In a groundbreaking clinical trial, the drug lenacapavir demonstrated a 100% success rate in preventing HIV infections among women and girls. This trial marks the most effective HIV prevention method ever recorded. Lenacapavir, already approved for treating HIV, requires only two injections per year to provide full protection. Recently, a phase I trial for once-yearly injections of lenacapavir was presented at a conference in San Francisco. These initial trials focused on safety in healthy volunteers and showed promising results. The potential of lenacapavir to be administered annually could significantly enhance HIV prevention strategies worldwide.
Jesse Morse, M.D.
@DrJesseMorse
·
Feb 28 Health insurance companies are VERY good at predicting decline and death.
Even though most Americans still continue to not believe, COVID and the COVID vaccine have changed our world indefinitely.
The sooner that you come to grips with this, the easier it will be to protect
Julia Kwasniewska
@J_Kwasniewska
·
Mar 12 Promising news! New annual injection designed to prevent #HIV has completed an early safety trial. Long-acting ARVs would play a key role in the global HIV response —but only if they become available to everyone who needs them, regardless of ability to pay
Vinay Prasad MD MPH
@VPrasadMDMPH
·
Feb 14 That’s correct.
Annual covid-19 shots have been given to people at ultra low risk of bad outcomes without any randomized data.
Even annual flu vaccines are assessed with very limited test-negative case control data. We have described methods to improve this.
Prof Peter Hotez MD PhD
@PeterHotez
·
Feb 6 Thanks for the question, and the ANS = $0 from both big pharma & cable news channels. The opposite: I develop low cost, often patent-free vaccines that actually bypass big pharma, 100 million doses administered at $2-4 per dose, showing there’s another path
Thumbs_Up_Bio
@thumbs_up_bio
·
Mar 14 19/
How Pricing Works in Biotech
A drug that meaningfully reduces steroids in a rare disease category can justify a $200K+ annual price tag.
Insurers have already backed similar models.
This is why Big Pharma is watching Efzo closely.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
